8-K: Tyra Biosciences Reports Q4/Full-Year 2025 Results

Tyra Biosciences announced its fourth quarter and full-year 2025 financial results, highlighting progress on its dabogratinib 3x3 strategy and a cash runway through at least 2027.

Summary

• Full-year 2025 net loss was $119.9 million, up from $86.5 million in 2024.
• Fourth quarter 2025 net loss was $33.8 million, up from $25.6 million in Q4 2024.
• Cash, cash equivalents, and marketable securities totaled $256.0 million as of December 31, 2025.
• Current cash is expected to fund operations through at least 2027.
• Launched dabogratinib 3x3 strategy focusing on 3 late-stage clinical studies (LG-UTUC, IR NMIBC, ACH) for 3 potential blockbuster indications.
• Prioritized portfolio by exiting metastatic bladder cancer to focus resources.
• Anticipates dosing first patient in Phase 2 LG-UTUC study (SURF303) in 2026.
• Expects initial three-month complete response data from Phase 2 IR NMIBC study (SURF302) by end of 1H 2026.
• Expects interim results from Phase 2 ACH study (BEACH301) safety sentinel cohort in 2H 2026, including 6-month average height velocity data.
• Strengthened leadership team with new Chief Operating Officer and Chief Regulatory Officer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update. While financial losses increased, the company has a solid cash runway and is strategically focusing its resources on high-potential clinical programs, which could drive long-term value.

Positives

• Strong cash position of $256.0 million as of December 31, 2025, providing a runway through at least 2027.
• Strategic focus on three high-potential indications (LG-UTUC, IR NMIBC, ACH) with the dabogratinib 3x3 strategy, aiming for blockbuster potential.
• Dabogratinib has demonstrated positive target engagement, favorable anti-tumor effects, and safety results in oncology, supporting once-daily dosing.
• Successful clearance of two of four dose levels in the BEACH301 study with no safety events reported.
• Strengthened leadership team with key appointments to advance clinical programs and prepare for potential pivotal studies.
• Dabogratinib received Orphan Drug Designation and Rare Pediatric Disease Designation for achondroplasia from the FDA.

Negatives

• Increased net loss for the full year 2025 to $119.9 million from $86.5 million in 2024.
• Increased net loss for Q4 2025 to $33.8 million from $25.6 million in Q4 2024.
• Research and Development (R&D) expenses increased to $102.9 million for full year 2025 from $80.1 million in 2024.
• General and Administrative (G&A) expenses increased to $29.8 million for full year 2025 from $24.1 million in 2024.
• Exited metastatic bladder cancer program (SURF301 is no longer recruiting patients), indicating a discontinuation of a previous development path.

Risks

• Interim results of a clinical trial are not necessarily indicative of final results and may materially change.
• Proof-of-concept results may fail to result in successful subsequent development of oral dabogratinib.
• Later developments with the FDA may be inconsistent with prior feedback.
• The SNP platform is novel and unproven and may never lead to successful product candidates or approved products.
• Potential delays in the commencement, recruitment, enrollment, data readouts, and completion of preclinical studies and clinical trials.
• Results from preclinical studies or early clinical trials may not be predictive of future results.
• Dependence on third parties in connection with manufacturing, research, and preclinical testing.
• Risk of expending limited resources on a particular product candidate and/or indication and failing to capitalize on others with greater potential.
• Acceptance by the FDA of INDs or similar regulatory submissions by foreign authorities for clinical trials is not guaranteed.
• An accelerated development or approval pathway may not be available or lead to a faster development process.
• Unexpected adverse side effects or inadequate efficacy of product candidates may limit their development, regulatory approval, and/or commercialization.
• Programs and prospects could be negatively impacted by developments relating to competitors.
• Regulatory and legislative developments in the United States and foreign countries, including healthcare and trade policies.
• Ability to obtain and maintain intellectual property protection for product candidates and proprietary technologies.
• Ability to establish marketing and sales capabilities to successfully commercialize any approved products.
• Capital resources may be used sooner than expected.

Future Outlook

Tyra Biosciences expects its current cash, cash equivalents, and marketable securities of $256.0 million to fund operations through at least 2027. The company anticipates dosing the first patient in the SURF303 LG-UTUC study in 2026, reporting initial three-month complete response data from the SURF302 IR NMIBC study by the end of 1H 2026, and interim results from the BEACH301 ACH safety sentinel cohort in 2H 2026.

Management Comments

• "At TYRA, we are following the science. The strength of the genetic and biological validation behind FGFR3 gives us conviction to concentrate our resources and strategy around indications where this target plays a central role." Todd Harris, Ph.D., CEO of TYRA.
• "Through our dabogratinib 3x3 strategy, we are deliberately deploying capital toward high unmet needs... where selective FGFR3 inhibition has the potential to make a meaningful impact for patients, while creating significant potential long-term value." Todd Harris, Ph.D., CEO of TYRA.
• "Oral dabogratinib reflects years of deliberate molecular optimization to achieve highly selective FGFR3 inhibition with a profile designed to balance potency, safety and convenience." Doug Warner, MD, Chief Medical Officer of TYRA.
• "The clinical data generated to date with more than 100 participants dosed reinforces our confidence in its potential efficacy and tolerability and supports once-daily (QD) dosing across our targeted indications." Doug Warner, MD, Chief Medical Officer of TYRA.
• "Exiting metastatic bladder cancer allows us to focus financial and operational resources on the three core indications within our dabogratinib 3x3 strategy that we believe offer the most compelling risk-adjusted opportunities." Alan Fuhrman, Chief Financial Officer of TYRA.

Industry Context

StockSavvy.ai notes that Tyra Biosciences' focus on FGFR3 inhibition aligns with a growing trend in precision oncology and rare disease drug development, where targeted therapies offer significant potential for improved patient outcomes and market differentiation. The strategic prioritization of specific indications, while discontinuing others, is a common practice in clinical-stage biotech to optimize resource allocation and accelerate development in areas with the highest perceived risk-adjusted return, especially given the high costs and failure rates in drug development.

Comparison to Industry Standards

• Tyra Biosciences' cash runway through at least 2027 with $256.0 million in cash, cash equivalents, and marketable securities is generally considered healthy for a clinical-stage biotechnology company, providing sufficient capital to advance multiple Phase 2 programs without immediate dilution concerns, comparable to peers like Mirati Therapeutics or Relay Therapeutics at similar development stages.
• The increase in R&D expenses to $102.9 million for full-year 2025 reflects typical escalation for a company with multiple active Phase 2 clinical trials, consistent with industry benchmarks for companies advancing lead candidates into later-stage development.
• The decision to exit metastatic bladder cancer (mUC) to focus on LG-UTUC, IR NMIBC, and ACH is a strategic move often seen in the biotech sector, similar to how companies like Blueprint Medicines have refined their pipeline focus to maximize success probabilities for specific indications.

Management Changes

Stakeholder Impact

• Shareholders: Potential for long-term value creation through focused clinical development in high-potential indications; increased net losses and R&D expenses indicate continued burn rate, but offset by a strong cash runway.
• Patients: Potential for new, effective oral treatment options for LG-UTUC, IR NMIBC, and achondroplasia with dabogratinib.
• Employees: Headcount growth indicated by increased G&A expenses, suggesting expansion in operations and leadership.

Next Steps

• Dose first patient in Phase 2 LG-UTUC study (SURF303) in 2026.
• Report initial three-month complete response data from Phase 2 IR NMIBC study (SURF302) by the end of 1H 2026.
• Report interim results from Phase 2 ACH study (BEACH301) safety sentinel cohort in 2H 2026, including 6-month average height velocity data and safety results.
• Publish final Phase 1 results from SURF301 in a future scientific publication.
• Continue advancing the in-house precision medicine discovery engine, SNP.

Key Dates

Recommendation

While Tyra Biosciences reported increased losses and expenses, which are negative, the company also demonstrated a clear strategic focus on high-potential indications for its lead asset, dabogratinib, backed by a solid cash runway through at least 2027. The progress in clinical trials and strengthening of the leadership team are positive developments. Given the early-stage nature of the clinical programs and the inherent risks in biotech, a "hold" recommendation is appropriate as investors await further clinical data readouts to assess the true potential of dabogratinib. The strategic shift to focus resources is a prudent move, but the success of these programs is still speculative.

Keywords

Tyra Biosciences, TYRA, biotechnology, clinical-stage, precision medicine, FGFR biology, dabogratinib, LG-UTUC, IR NMIBC, achondroplasia, oncology, skeletal dysplasia, financial results, Q4 2025, full-year 2025, clinical trials, drug development, Orphan Drug Designation, Rare Pediatric Disease Designation, SNP platform